Cargando…
Epigenetically inactivated RASSF1A as a tumor biomarker
RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292865/ https://www.ncbi.nlm.nih.gov/pubmed/33175673 http://dx.doi.org/10.17305/bjbms.2020.5219 |
_version_ | 1783724908866437120 |
---|---|
author | Raos, Dora Ulamec, Monika Bojanac, Ana Katusic Bulic-Jakus, Floriana Jezek, Davor Sincic, Nino |
author_facet | Raos, Dora Ulamec, Monika Bojanac, Ana Katusic Bulic-Jakus, Floriana Jezek, Davor Sincic, Nino |
author_sort | Raos, Dora |
collection | PubMed |
description | RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A was detected in various cancer types and led to significant interest; current research on RASSF1A promoter methylation focuses on its roles as an epigenetic tumor biomarker. Typically, researchers analyzed genomic DNA (gDNA) to measure the amount of RASSF1A promoter methylation. Cell-free DNA (cfDNA) from liquid biopsies is a recent development showing promise as an early cancer diagnostic tool using biomarkers, such as RASSF1A. This review discusses the evidence on aberrantly methylated RASSF1A in gDNA and cfDNA from different cancer types and its utility for early cancer diagnosis, prognosis, and surveillance. We compared methylation frequencies of RASSF1A in gDNA and cfDNA in various cancer types. The weaknesses and strengths of these analyses are discussed. In conclusion, although the importance of RASSSF1A methylation to cancer has been established and is included in several diagnostic panels, its diagnostic utility is still experimental. |
format | Online Article Text |
id | pubmed-8292865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-82928652021-08-01 Epigenetically inactivated RASSF1A as a tumor biomarker Raos, Dora Ulamec, Monika Bojanac, Ana Katusic Bulic-Jakus, Floriana Jezek, Davor Sincic, Nino Bosn J Basic Med Sci Review Article RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A was detected in various cancer types and led to significant interest; current research on RASSF1A promoter methylation focuses on its roles as an epigenetic tumor biomarker. Typically, researchers analyzed genomic DNA (gDNA) to measure the amount of RASSF1A promoter methylation. Cell-free DNA (cfDNA) from liquid biopsies is a recent development showing promise as an early cancer diagnostic tool using biomarkers, such as RASSF1A. This review discusses the evidence on aberrantly methylated RASSF1A in gDNA and cfDNA from different cancer types and its utility for early cancer diagnosis, prognosis, and surveillance. We compared methylation frequencies of RASSF1A in gDNA and cfDNA in various cancer types. The weaknesses and strengths of these analyses are discussed. In conclusion, although the importance of RASSSF1A methylation to cancer has been established and is included in several diagnostic panels, its diagnostic utility is still experimental. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2021-08 /pmc/articles/PMC8292865/ /pubmed/33175673 http://dx.doi.org/10.17305/bjbms.2020.5219 Text en Copyright: © The Author(s) (2021) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Review Article Raos, Dora Ulamec, Monika Bojanac, Ana Katusic Bulic-Jakus, Floriana Jezek, Davor Sincic, Nino Epigenetically inactivated RASSF1A as a tumor biomarker |
title | Epigenetically inactivated RASSF1A as a tumor biomarker |
title_full | Epigenetically inactivated RASSF1A as a tumor biomarker |
title_fullStr | Epigenetically inactivated RASSF1A as a tumor biomarker |
title_full_unstemmed | Epigenetically inactivated RASSF1A as a tumor biomarker |
title_short | Epigenetically inactivated RASSF1A as a tumor biomarker |
title_sort | epigenetically inactivated rassf1a as a tumor biomarker |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292865/ https://www.ncbi.nlm.nih.gov/pubmed/33175673 http://dx.doi.org/10.17305/bjbms.2020.5219 |
work_keys_str_mv | AT raosdora epigeneticallyinactivatedrassf1aasatumorbiomarker AT ulamecmonika epigeneticallyinactivatedrassf1aasatumorbiomarker AT bojanacanakatusic epigeneticallyinactivatedrassf1aasatumorbiomarker AT bulicjakusfloriana epigeneticallyinactivatedrassf1aasatumorbiomarker AT jezekdavor epigeneticallyinactivatedrassf1aasatumorbiomarker AT sincicnino epigeneticallyinactivatedrassf1aasatumorbiomarker |